Core Insights - TTEC has appointed Chris Brown as president of TTEC Digital, effective immediately, succeeding David Seybold who will depart on April 30, 2026 [1][2] - Brown's leadership is expected to drive TTEC Digital's global strategy, P&L management, and operational execution, leveraging his extensive experience and institutional knowledge [2][3] Leadership Transition - David Seybold will remain with TTEC until April 30, 2026, to ensure a smooth transition [2] - Chris Brown has been with TTEC since 2015 and previously served as Chief of Staff to the Chairman and CEO, focusing on corporate development and strategic partnerships [3][4] Chris Brown's Background - Brown has over two decades of experience advising technology and services firms on M&A, capital markets, and strategic transformation, with a focus on SaaS, AI, and cloud sectors [4] - He has held senior leadership roles in investment banking at UBS and management consulting at Mercer, and played a key role in the acquisition of Liquid Robotics by Boeing [4] TTEC Digital's Vision - Brown emphasized the unique capabilities of TTEC Digital in combining talent, technology partnerships, and AI expertise to deliver value for enterprise clients globally [5] - TTEC Digital is recognized as the world's largest pureplay CX technology and services provider, enhancing customer engagement and operational efficiency [5][6] Company Overview - TTEC Holdings, Inc. is a global consulting, technology, and managed services company focused on data, AI, and customer experience [6] - The company offers outcome-based solutions that span the entire enterprise and improve customer interactions across various channels [6]

Core Insights - Theriva Biologics has successfully engaged with the FDA, allowing the advancement into a proposed Phase 3 clinical trial for VCN-01 in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma (PDAC) [1][4] Group 1: Clinical Trial Design and Feedback - The FDA has provided general agreement on Theriva's proposed design for the Phase 3 clinical trial, which is aligned with the successful VIRAGE Phase 2 trial that demonstrated improved overall survival (OS), progression-free survival (PFS), and Duration of Response (DoR) in patients receiving VCN-01 with standard-of-care chemotherapy [2] - The Phase 3 trial will include repeat dosing of VCN-01 and an adaptive design to optimize timelines and outcomes, based on the positive results from the Phase 2 trial [2][4] - The FDA has indicated that a potential biologics licensing application (BLA) for VCN-01 could be supported by the proposed Phase 3 trial, which will compare VCN-01 plus chemotherapy to chemotherapy plus placebo [3] Group 2: Company Strategy and Future Plans - The combined feedback from the FDA and EMA allows the company to finalize the protocol for the pivotal Phase 3 clinical trial and pursue strategic funding opportunities [1][4] - The CEO of Theriva Biologics expressed optimism that administering multiple macrocycles of VCN-01 alongside chemotherapy may further enhance patient outcomes [4] - The company aims to deliver a novel treatment option for patients with difficult-to-treat solid tumors, leveraging the insights gained from regulatory feedback [4] Group 3: Background on PDAC and VCN-01 - Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of pancreatic tumors and is often diagnosed at advanced stages, making treatment challenging [5] - VCN-01 is an oncolytic adenovirus designed to selectively replicate within tumor cells, degrade tumor stroma, and enhance the efficacy of co-administered chemotherapy [6][7] - The therapeutic approach of VCN-01 aims to improve access to chemotherapy and stimulate an immune response against the tumor [7]

Core Viewpoint - The launch of Kakegurui ALL IN expands CTW's game library to 36 titles, enhancing its offerings on the G123.jp platform, which provides free browser-based games without the need for registration or downloads [1][3]. Company Overview - CTW Cayman is a leading game platform company that provides global access to web-based, free-to-play games inspired by popular Japanese animations [4]. - The company operates its flagship HTML5 platform G123.jp, which was recognized as the largest anime IP-based H5 game platform in the world in 2023 in terms of gross billings according to a Frost & Sullivan Report [4]. - CTW focuses on securing licenses for compelling intellectual property and expanding its portfolio with games that appeal to diverse player preferences [3]. Game Launch Details - Kakegurui ALL IN is based on a popular manga and anime series that features high-stakes psychological warfare and strategic gameplay, appealing to a global fan base [2][3]. - The game is expected to resonate with players seeking high-quality gaming experiences, particularly among Western audiences due to its increasing traction and global streaming distribution [3]. - The company has plans to launch additional games, including Miss Kobayashi's Dragon Maid Fantasia, High School of the Dead Day 0, and Cute High Earth Defense Club Love Macho, further expanding its game library [3][5]. Market Position and Strategy - CTW aims to provide a comprehensive platform that helps game developers generate revenue from Japanese anime IP by reaching a global player audience [4]. - The company collaborates with skilled game developers to deliver high-quality, animation-themed gaming experiences worldwide [4].

Core Viewpoint - Enlivex Ltd. has received FDA clearance for its Investigational New Drug application for Allocetra™, an immunotherapy aimed at treating moderate-to-severe age-related symptomatic primary knee osteoarthritis, marking a significant milestone for the company [1][4]. Company Overview - Enlivex is a quality longevity company focused on developing Allocetra™, a clinical-stage immunotherapy targeting inflammatory conditions associated with aging, particularly age-related osteoarthritis [5][6]. - The company operates a dual-engine value creation model that combines the development of therapeutics with a prediction markets treasury strategy [3][6]. Clinical Trial Details - The FDA's clearance allows Enlivex to start a global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial to assess the efficacy and safety of Allocetra™ in patients with knee osteoarthritis [2][4]. - The trial is designed to evaluate key efficacy endpoints, including changes in pain and physical function at three and six months post-treatment, along with quality-of-life measures and functional mobility assessments [4][8]. Market Context - Knee osteoarthritis is a prevalent and disabling condition affecting over 32 million Americans today, with projections indicating that 78 million will be affected by 2040 [2][7]. - Currently, there are no approved disease-modifying therapies for knee osteoarthritis, and treatment options are primarily focused on pain relief, intra-articular steroids, or surgery [7].

Core Viewpoint - Daré Bioscience is introducing DARE to PLAY™ Sildenafil Cream, a groundbreaking topical arousal cream specifically designed for women, aiming to address the long-ignored area of women's sexual health [1][5][21]. Product Overview - DARE to PLAY™ is the first clinically studied topical arousal cream for women, utilizing sildenafil, the same active ingredient found in Viagra, to enhance genital blood flow and improve arousal sensations [2][4][14]. - The cream is designed to be applied topically, providing localized effects within 10-15 minutes, unlike oral sildenafil [6][17]. Market Opportunity - Approximately 20 million women in the U.S. face challenges related to genital arousal, with no FDA-approved therapeutics currently available to address this need [17]. - The introduction of DARE to PLAY™ aims to fill this significant gap in the market, providing a science-backed solution for women's sexual health [5][21]. Clinical Evidence - DARE to PLAY™ has undergone clinical studies focused on female physiology and response, demonstrating its effectiveness in increasing genital blood flow and enhancing natural arousal sensations [4][19]. - The product is supported by peer-reviewed research published in reputable medical journals, ensuring its credibility and scientific rigor [19][21]. Regulatory and Manufacturing Aspects - DARE to PLAY™ will be available as a Section 503B compounded product, manufactured in compliance with current Good Manufacturing Practice (cGMP) regulations, ensuring quality and consistency [15][18]. - The company is pursuing FDA approval for its proprietary sildenafil cream formulation while providing earlier access to patients through the compounded product [15][19]. Company Mission and Vision - Daré Bioscience is dedicated to transforming women's sexual and reproductive health through innovative science, focusing on closing the gap between promising research and real-world solutions [21][22]. - The company emphasizes the need for increased investment and attention in women's health, advocating for evidence-based solutions that have been historically underfunded and underserved [5][22].

Core Insights - The company is positioned for scalable deployment across AI, industrial, and healthcare markets due to advancements in regulatory pathways, a fully secured supply chain, and growing commercial traction [1] Regulatory Progress - The company is advancing its engagement with the U.S. Nuclear Regulatory Commission (NRC), nearing completion of the pre-application phase, which supports readiness for Construction Permit Application (CPA) submission [2] Design and Funding - The SOLO™ reactor design is complete, with no further R&D expected for first-of-a-kind (FOAK) deployment, and existing capital is expected to fully fund licensing, construction, and initial operations [3] Supply Chain and Manufacturing - The company has secured a full nuclear-grade supply chain and initiated pre-fabrication and manufacturing activities, significantly de-risking deployment timelines and enabling scalable production [3] Manufacturing Model - The company employs a factory-based, partner-driven production strategy, which is expected to support rapid scaling from hundreds to potentially thousands of units annually over time [4] Commercial Opportunities - Strong demand is observed across data centers, industrial applications, infrastructure, and healthcare, with approximately 200 non-binding pre-commercial unit commitments representing around $4 billion in potential value [4] Deployment Timeline - The company targets FOAK deployment beginning in 2027, with commercialization in 2028, supported by a streamlined licensing approach and standardized reactor design [5] Strategic Positioning - Recent initiatives include a pilot deployment for next-generation AI data centers, with potential for significant scaling as demand for reliable power increases [6] Product Extensions - The SOLO™ reactor can produce multiple outputs, including electricity, process heat, and radioisotopes, expanding the company's addressable market into high-margin healthcare and advanced industrial applications [6] Global Availability - The SOLO™ reactor is anticipated to be available globally within the next three years, addressing pressing global energy demands with a market-ready solution [9] Versatile Applications - The SOLO™ reactor offers CO2-free, behind-the-meter, and off-grid power solutions for various sectors, including data centers and large-scale industrial operations, and can also produce radioisotopes for medical applications [10]

Core Viewpoint - NowVertical Group Inc. has expanded its cloud data migration engagement with a large enterprise client, leveraging AI-powered migration tools to enhance efficiency and project timelines [1][2]. Group 1: Project Expansion and Financials - The AI tools reduced the estimated delivery effort from 2,700 hours to 250 hours, leading to an accelerated project timeline and prompting the client to expand the project scope [2]. - The client has signed an additional $250,000 for the expansion in Q1, building on over $2.5 million of work delivered in the past 12 months and over $7.5 million in the last four years [2]. Group 2: Technology and Services - NowVertical's AI-enabled delivery tools automate complex data engineering tasks, improving delivery speed while maintaining quality [3]. - The engagement involves migrating enterprise data infrastructure to a Google Cloud Platform environment, supporting analytics, AI, and data governance initiatives [3]. Group 3: Company Overview - NowVertical is a global data and analytics company that transforms data into business value using AI, enabling clients to optimize decision-making and improve operational efficiency [5]. - The company is growing both organically and through strategic acquisitions, offering a comprehensive suite of solutions and services [5].

Core Viewpoint - Indonesia Energy Corporation (IEC) is progressing with its drilling plans for two new wells in the Kruh Block, with drilling expected to commence within approximately 60 days, coinciding with rising global oil prices due to geopolitical tensions in the Middle East [1][2]. Company Developments - IEC has completed the construction of drilling pads for the K-29 and WK-5 wells, and all necessary long lead items, including drilling pipe, drill bits, and wellheads, have been delivered [3]. - The drilling rig, BMA 9, has been selected and is en route to the first drilling pad, with inspections successfully completed [3]. - Delays in drilling operations were caused by severe flooding in Sumatra, which damaged the planned access road; however, IEC has secured permits to use an alternative main road for the rig's transportation [3]. Strategic Outlook - The President of IEC, Frank Ingriselli, expressed optimism about the drilling plans, emphasizing the company's world-class assets in Indonesia and the potential for maximizing returns and growing shareholder value in the current favorable oil market [4]. - IEC's principal assets include the Kruh Block (63,000 acres) and the Citarum Block (195,000 acres), both located onshore in Indonesia [5].

Core Viewpoint - Cheer Holding, Inc. reported solid financial performance for the fiscal year ended December 31, 2025, with a focus on artificial intelligence and plans for global expansion [2][6]. Financial Highlights - Total revenues increased by 1.1% to $148.8 million, compared to $147.2 million in 2024 [6]. - Income from operations rose by 2.7% to $26.3 million, up from $25.6 million in 2024 [6]. - Net income attributable to shareholders was $25.6 million, slightly down from $26.0 million in the previous year [6]. - Cash and cash equivalents increased to $242.1 million as of December 31, 2025, from $197.7 million at the end of 2024 [6]. - Cumulative app downloads reached 550 million, a 5.0% increase from 523.3 million as of December 31, 2024 [6]. Operational Highlights - Cheer Holding operates a comprehensive digital ecosystem that integrates platforms, applications, technology, and industry, focusing on AI-driven content creation, e-commerce, and metaverse development [4]. - The company is initiating a strategic pivot towards global markets, with a dedicated AI portrait and video product line expected to begin beta testing in the second quarter of 2026 [6].

Core Viewpoint - Tempest Therapeutics, Inc. has announced a private placement of common stock and warrants, aiming to raise approximately $2 million upfront, with potential additional gross proceeds of up to $4 million upon full exercise of the warrants [1][3]. Group 1: Offering Details - The company will sell 925,927 shares of common stock and warrants at a combined purchase price of $2.16 per share [1]. - The series A and short-term series B warrants will have an exercise price of $2.16 per share and will be exercisable following stockholder approval [1]. - The private placement is expected to close on or about March 23, 2026, subject to customary closing conditions [1]. Group 2: Financial Implications - The gross proceeds from the offering are expected to be approximately $2 million before deducting fees and expenses [3]. - If fully exercised, the series A and short-term series B warrants could provide an additional $4 million in gross proceeds [3]. - The net proceeds from the offering will be used for working capital and general corporate purposes [3]. Group 3: Regulatory Information - The securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Securities Act or applicable state laws [4]. - The company has agreed to file a resale registration statement covering the securities as part of a registration rights agreement with investors [4]. Group 4: Company Overview - Tempest Therapeutics is a clinical-stage biotechnology company focused on developing advanced CAR-T cell therapy product candidates for cancer treatment [6]. - The company is headquartered in Brisbane, California [6].